Caribou halts its allogeneic CAR T programs as funding dries up Facing a tight financing market, the CRISPR biotech will wind down two off-the-shelf cell therapies as investor money shifts toward in vivo CAR T. Written byAndrea Corona

Caribou halts its allogeneic CAR T programs as funding dries up Facing a tight financing market, the CRISPR biotech will wind down two off-the-shelf cell therapies as investor money shifts toward in vivo CAR T. Written byAndrea Corona https://www.drugdiscoverynews.com/caribou-halts-its-allogeneic-car-t-programs-as-funding-dries-up-17584?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-_VKkkojNK1QpvONG19i16LDx1hyhVxpBuGF9WqsjO_WAAxM-6O8sg2-UCZz0I2nOOLWiRPOzAFFRmK9cTfxw-i_CrfSg&_hsmi=444630187&utm_content=444630187&utm_source=hs_email For years, allogeneic CAR T cell therapy carried one of the field’s biggest promises: cancer-fighting cells made from healthy donors, stocked in advance, and ready the moment a patient needed them. Caribou Biosciences built its pipeline around that vision, using CRISPR genome editing to engineer donor cells that could persist and fight tumors. On October 6th, the company announced it would shelve both of its allogeneic chimeric antigen receptor (CAR) T cell therapy programs, including one ready for a Phase 3 trial.